(ALC) Alcon - NYSE
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NYSE (USA) | Market Cap: 32.583m USD | Total Return: -25.3% in 12m
Avg Turnover: 150M
EPS Trend: 85.9%
Qual. Beats: 1
Rev. Trend: 99.1%
Qual. Beats: -1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Alcon AG (ALC) is a Swiss-based medical device company specializing in eye care through two primary segments: Surgical and Vision Care. The Surgical division manufactures equipment, diagnostic systems, and intraocular lenses (IOLs) for cataract, vitreoretinal, and refractive procedures. The Vision Care segment focuses on daily and reusable contact lenses alongside a portfolio of ocular health products for dry eye, allergies, and glaucoma.
The ophthalmic device sector is characterized by high barriers to entry due to stringent regulatory requirements and the specialized manufacturing precision needed for implantable optics. Alcon utilizes a recurring revenue business model by pairing its installed base of surgical consoles with high-volume sales of proprietary consumables and single-use procedure packs.
For a deeper analysis of these market dynamics, you may wish to examine the historical performance data available on ValueRay.
Headquartered in Geneva, the company supports global ophthalmic surgery through integrated digital platforms and advanced visualization systems like the NGENUITY 3D. Its product suite covers the full spectrum of vision correction, from corrective contact lenses to laser-assisted surgical interventions.
- Adoption of premium intraocular lenses drives surgical segment revenue and margin growth
- Expansion of daily disposable contact lens portfolio increases recurring vision care sales
- Global aging demographics sustain long-term demand for cataract and vitreoretinal surgical procedures
- Research and development spending on next-generation surgical equipment influences operating margins
- Strategic expansion into emerging markets offsets pricing pressures in mature eye care regions
| Net Income: 815.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.15 > 1.0 |
| NWC/Revenue: 34.36% < 20% (prev 38.50%; Δ -4.14% < -1%) |
| CFO/TA 0.07 > 3% & CFO 2.27b > Net Income 815.3m |
| Net Debt (4.15b) to EBITDA (2.65b): 1.57 < 3 |
| Current Ratio: 2.20 > 1.5 & < 3 |
| Outstanding Shares: last quarter (490.2m) vs 12m ago -1.57% < -2% |
| Gross Margin: 54.95% > 18% (prev 55.55%; Δ -0.60% > 0.5%) |
| Asset Turnover: 33.70% > 50% (prev 32.01%; Δ 1.69% > 0%) |
| Interest Coverage Ratio: 6.32 > 6 (EBIT TTM 1.30b / Interest Expense TTM 206.0m) |
| DSRI: 1.02 (Receivables 2.02b/1.86b, Revenue 10.6b/9.93b) |
| GMI: 1.01 (GM 55.55% / 54.95%) |
| AQI: 0.97 (AQ_t 0.63 / AQ_t-1 0.65) |
| SGI: 1.07 (Revenue 10.6b / 9.93b) |
| TATA: -0.05 (NI 815.3m - CFO 2.27b) / TA 31.8b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of June 11, 2026, the stock is trading at USD 66.11 with a total of 1,134,641 shares traded.
Over the past week, the price has changed by +2.94%,
over one month by +6.59%,
over three months by -17.63% and
over the past year by -25.32%.
Alcon has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy ALC.
- StrongBuy: 15
- Buy: 6
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 88.5 | 33.9% |
P/E Trailing = 40.006
P/E Forward = 19.305
P/S = 3.0641
P/B = 1.4672
P/EG = 1.4954
Revenue TTM = 10.6b USD
EBIT TTM = 1.30b USD
EBITDA TTM = 2.65b USD
Long Term Debt = 4.16b USD (from longTermDebt, last quarter)
Short Term Debt = 660.6m USD (from shortTermDebt, last quarter)
Debt = 5.82b USD (from shortLongTermDebtTotal, last quarter) + Leases 528.0m
Net Debt = 4.15b USD (calculated: Debt 5.82b - CCE 1.67b)
Enterprise Value = 36.7b USD (32.6b + Debt 5.82b - CCE 1.67b)
Interest Coverage Ratio = 6.32 (Ebit TTM 1.30b / Interest Expense TTM 206.0m)
EV/FCF = 21.55x (Enterprise Value 36.7b / FCF TTM 1.70b)
FCF Yield = 4.64% (FCF TTM 1.70b / Enterprise Value 36.7b)
FCF Margin = 16.11% (FCF TTM 1.70b / Revenue TTM 10.6b)
Net Margin = 7.71% (Net Income TTM 815.3m / Revenue TTM 10.6b)
Gross Margin = 54.95% ((Revenue TTM 10.6b - Cost of Revenue TTM 4.77b) / Revenue TTM)
Gross Margin QoQ = 56.36% (prev 54.19%)
Tobins Q-Ratio = 1.16 (Enterprise Value 36.7b / Total Assets 31.8b)
Interest Expense / Debt = 3.54% (Interest Expense 206.0m / Debt 5.82b)
Taxrate = 16.92% (166.0m / 981.3m)
NOPAT = 1.08b (EBIT 1.30b * (1 - 16.92%))
Current Ratio = 2.20 (Total Current Assets 6.66b / Total Current Liabilities 3.02b)
Debt / Equity = 0.26 (Debt 5.82b / totalStockholderEquity, last quarter 22.3b)
Debt / EBITDA = 1.57 (Net Debt 4.15b / EBITDA 2.65b)
Debt / FCF = 2.44 (Net Debt 4.15b / FCF TTM 1.70b)
Total Stockholder Equity = 22.1b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.60% (Net Income 815.3m / Total Assets 31.8b)
RoE = 3.69% (Net Income TTM 815.3m / Total Stockholder Equity 22.1b)
RoCE = 4.96% (EBIT 1.30b / Capital Employed (Equity 22.1b + L.T.Debt 4.16b))
RoIC = 3.75% (NOPAT 1.08b / Invested Capital 28.9b)
WACC = 6.43% (E(32.6b)/V(38.4b) * Re(7.05%) + D(5.82b)/V(38.4b) * Rd(3.54%) * (1-Tc(0.17)))
Discount Rate = 7.05% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -11.11 | Cagr: -0.27%
[DCF] Terminal Value 76.15% ; FCFF base≈1.67b ; Y1≈1.75b ; Y5≈2.03b
[DCF] Fair Price = 55.69 (EV 31.3b - Net Debt 4.15b = Equity 27.2b / Shares 487.7m; r=8.35% [WACC [floored]]; 5y FCF grow 5.57% → 2.50% )
EPS Correlation: 85.87 | EPS CAGR: 25.54% | SUE: 0.89 | # QB: 1
Revenue Correlation: 99.12 | Revenue CAGR: 5.12% | SUE: -1.61 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.75 | Chg30d=-5.18% | Revisions=-38% | Analysts=14
EPS next Quarter (2026-09-30): EPS=0.56 | Chg30d=-5.56% | Revisions=+0% | Analysts=8
EPS current Year (2026-12-31): EPS=3.47 | Chg30d=+0.86% | Revisions=+65% | GrowthEPS=+12.9% | GrowthRev=+7.0%
EPS next Year (2027-12-31): EPS=3.97 | Chg30d=+1.07% | Revisions=+48% | GrowthEPS=+14.5% | GrowthRev=+6.3%
[Analyst] Revisions Ratio: +65%